Shockwave Medical Stock Price, News & Analysis (NASDAQ:SWAV)

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shockwave Medical in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SWAV shares.
View SWAV analyst ratings or view top-rated stocks.

10 analysts have issued 1 year price objectives for Shockwave Medical's stock. Their SWAV share price targets range from $218.00 to $315.00. On average, they expect the company's stock price to reach $269.78 in the next year. This suggests a possible upside of 58.3% from the stock's current price.
View analysts price targets for SWAV or view top-rated stocks among Wall Street analysts.

Shockwave Medical's stock was trading at $205.61 at the beginning of the year. Since then, SWAV stock has decreased by 17.1% and is now trading at $170.39.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our SWAV earnings forecast.

Shockwave Medical, Inc. (NASDAQ:SWAV) announced its earnings results on Monday, November, 6th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.81 by $0.11. The company earned $186.02 million during the quarter, compared to the consensus estimate of $184.71 million. Shockwave Medical had a trailing twelve-month return on equity of 42.41% and a net margin of 36.33%. The firm's revenue for the quarter was up 41.6% on a year-over-year basis. During the same quarter last year, the business posted $0.92 earnings per share.

ETFs with the largest weight of Shockwave Medical (NASDAQ:SWAV) stock in their portfolio include Neuberger Berman Disrupters ETF (NBDS), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), First Trust Indxx Medical Devices ETF (MDEV), Invesco S&P MidCap 400 Pure Growth ETF (RFG), Alger Mid Cap 40 ETF (FRTY), WisdomTree U.S. Growth & Momentum Fund (WGRO) and First Trust Health Care AlphaDEX Fund (FXH).

8 employees have rated Shockwave Medical Chief Executive Officer Doug Godshall on Glassdoor.com. Doug Godshall has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Shockwave Medical investors own include NVIDIA (NVDA), Walt Disney (DIS), Block (SQ), Trade Desk (TTD), Salesforce (CRM), Roku (ROKU), PayPal (PYPL), DexCom (DXCM), Alibaba Group (BABA) and Okta (OKTA).

(SWAV) raised $75 million in an initial public offering (IPO) on Thursday, March 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

Shockwave Medical's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (6.85%), Artisan Partners Limited Partnership (3.80%), Invesco Ltd. (1.92%), Allspring Global Investments Holdings LLC (1.76%), Morgan Stanley (1.17%) and Canada Pension Plan Investment Board (1.05%). Insiders that own company stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frank T Watkins, Frank T Watkins, Isaac Zacharias, Kurt F Gallo, Laura Francis, Maria Sainz, Sara Toyloy and Trinh Phung.
View institutional ownership trends.

Shares of SWAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.